Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' quadrivalent influenza vaccine · 1 trial · 1 indication
Antibody titers were expressed as Geometric mean titers (GMTs).The vaccine influenza strains included A/Solomon Islands,A/Wisconsin,B/Malaysia and B/Jiangsu antigens.
| Arm | Type | Description |
|---|---|---|
| Quadrivalent influenza vaccine GSK 2115160A Group 1 | EXPERIMENTAL | Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Quadrivalent influenza vaccine GSK 2115160A Group 2 | EXPERIMENTAL | Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Trivalent influenza vaccine GSK 2115160A Group 1 | ACTIVE_COMPARATOR | Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Trivalent influenza vaccine GSK 2115160A Group 2 | ACTIVE_COMPARATOR | Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0 |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' quadrivalent influenza vaccine | BIOLOGICAL | Single intramuscular dose on Day 0. |
| GSK Biologicals' trivalent influenza vaccine | BIOLOGICAL | Single intramuscular dose on Day 0. |
Inclusion Criteria: * Healthy subjects as established by medical history and clinical examination before entering into the study. * Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and inclu...
GSK Biologicals' quadrivalent influenza vaccine is an investigational vaccine being developed for the prevention of influenza. It is designed to provide immunity against four influenza virus strains. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
GSK Biologicals' quadrivalent influenza vaccine is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The vaccine is part of GSK's infectious disease portfolio and is currently in Phase 1 clinical development.
GSK Biologicals' quadrivalent influenza vaccine is in Phase 1 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory agencies. The vaccine is being studied in a completed Phase 1 trial to evaluate its immunogenicity and safety in adults.
GSK Biologicals' quadrivalent influenza vaccine has been studied in one completed Phase 1 clinical trial, identified as NCT00714285. This trial, titled 'Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults,' enrolled 420 healthy adult participants aged 18 years and older in Czechia.
No, GSK Biologicals' quadrivalent influenza vaccine is not a monoclonal antibody. Although the modality is listed as a monoclonal antibody in some databases, the product is described as a quadrivalent influenza vaccine, which is a vaccine designed to elicit an immune response against four influenza strains, not a monoclonal antibody therapeutic.